



Cite this: *RSC Adv.*, 2019, 9, 2325

# Efficient synthesis of Ibrutinib chiral intermediate in high space-time yield by recombinant *E. coli* co-expressing alcohol dehydrogenase and glucose dehydrogenase†

Yitong Chen, Baodi Ma, \* Songshuang Cao, Xiaomei Wu and Yi Xu\*

The production of (*S*)-*N*-*boc*-3-hydroxy piperidine (NBHP) via asymmetric bioreduction of 1-*boc*-3-piperidinone with reductase is impeded by the need for expensive coenzymes NAD(P)H. In order to regenerate the coenzyme *in situ*, the gene of alcohol dehydrogenase from *Thermoanaerobacter brockii* and glucose dehydrogenase from *Bacillus subtilis* were ligated into the multiple cloning sites of pRSFDuet-1 plasmid to construct the recombinant *Escherichia* BL21 (DE3) that co-expressing alcohol dehydrogenase and glucose dehydrogenase. Different culture conditions including the medium composition, inducer and pH etc were systematically investigated to improve the enzyme production. The enzyme activity was increased more than 11-fold under optimal culture condition, from 12.7 to 139.8 U L<sup>-1</sup>. In the further work, the asymmetric reduction of 1-*boc*-3-piperidinone by whole cells of recombinant *E. coli* was systematic optimized to increase the substrate concentration and reaction efficiency. At last, *S*-NBHP (>99% ee) was prepared at 500 mM substrate concentration without external addition of cofactors. The conversion of *S*-NBHP reached 96.2% within merely 3 h, corresponding a high space-time yield around 774 g L<sup>-1</sup> d<sup>-1</sup>. All these results demonstrated the potential of recombinant *E. coli* BL21 (DE3) coupled expressing alcohol dehydrogenase and glucose dehydrogenase for efficient synthesis of *S*-NBHP.

Received 30th September 2018  
Accepted 10th January 2019

DOI: 10.1039/c8ra08100j

rsc.li/rsc-advances

## 1. Introduction

Chiral hydroxyl piperidines and their derivatives are of great importance in the pharmaceutical industry and many of them have pharmaceutical activity, such as anti-tumor agents, antibiotics and anti-senile dementia agents.<sup>1</sup> Many bioactive molecules and active pharmaceutical ingredients (API) contain one or more piperidine rings.<sup>2,3</sup> Ibrutinib is a targeted anti-cancer drug that inhibits Bruton tyrosine kinase for the treatment of mantle cell lymphoma. (*S*)-*N*-*boc*-3-hydroxy piperidine (NBHP) is a key intermediate in the synthesis of Ibrutinib.

Currently, several approaches have been developed for the synthesis of chiral alcohol, including classic diastereomeric resolution,<sup>4</sup> asymmetric synthesis,<sup>5</sup> and asymmetric reduction.<sup>6</sup> Of these methods, asymmetric bioreduction has attracted extensive attention due to the high stereoselectivity, mild condition and 100% theoretical yield. Asymmetric bioreduction has been successfully applied in the preparation of (*S*)-(4-chlorophenyl)-(pyridin-2-yl)methanol,<sup>7</sup> (*R*)-1-phenyl-1,2-

ethanediol<sup>8</sup> and ethyl (*R*)-4-chloro-3-hydroxybutanoate<sup>9</sup> etc. However, there were few reports about the synthesis of (*S*)-*N*-*boc*-3-hydroxy piperidine (NBHP) via asymmetric bioreduction. Romain Lacheretz *et al.*<sup>10</sup> used the tissue of *Daucus carota* as biocatalyst to reduce 1-*boc*-3-piperidinone, and moderate chiral purity (ee 95%) and low yield of product (73%) was obtained. Other reductases reported to reduce 1-*boc*-3-piperidinone more efficiently were the alcohol dehydrogenase from *Thermoanaerobacter brockii*,<sup>11</sup> and KR-110 screened from a commercial ketoreductase library.<sup>12</sup> However, expensive exogenous coenzyme has to be added to the reaction system to allow the reaction to proceed.

The expensive cofactor NAD(P)H was required in the bioreduction process, thus its regeneration attracted extensive attention in the last few decades. As early as the 1980s, researchers began to develop different cofactor regeneration systems, including biological (intracellular coenzyme regeneration, substrate coupling method and enzyme coupling method), electrochemical, photochemical and pure chemistry and so on. Currently, enzyme coupling and substrate coupling have been favoured.<sup>13,14</sup> The reduction of the substrate and the regeneration of the coenzyme are performed by two different enzymes in the double enzyme-coupled system. At present, formate dehydrogenase (FDH) and glucose dehydrogenase

School of Chemical and Environmental Engineering, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China. E-mail: xuyi@sit.edu.cn; mabaodi2005@163.com

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra08100j



(GDH) mediated coenzyme regeneration system proved to be feasible in the industrial application.<sup>15</sup> There are many successful examples using GDH to construct a coenzyme regeneration system. For instance, Gröger *et al.* had constructed a 'Designer cell' containing GDH from *Bacillus subtilis* and ADH from *Rhodococcus erythropolis*, and it had been used for the asymmetric reduction of a variety of aryl ketones in the absence of exogenous coenzyme.<sup>16,17</sup> However, no such report on the production of *S*-NBHP was found.

The alcohol dehydrogenase from *Thermoanaerobacter brockii* (TbADH) was an attractive ADH in the biotechnology due to its high thermostability, excellent activity and enantioselectivity for the reduction of 1-boc-3-piperidinone.<sup>11</sup> In current research, a novel two-enzyme (ADH and GDH) co-overexpressing system was developed for efficient asymmetric reduction of 1-boc-3-piperidinone without needing exogenous coenzyme. The vector pRSFDuet-1 contains two multiple cloning sites and each of them is preceded by a T7 promoter and ribosome binding site. In present work, the gene TbADH<sup>18</sup> and glucose dehydrogenase from *Bacillus subtilis* (BsGDH)<sup>19</sup> were designed to ligate into the multiple cloning sites (MCS) of vector pRSFDuet-1 and construct a recombinant *E. coli* BL21 (DE3) with both TbADH and BsGDH activity. *S*-NBHP can be prepared *via* the asymmetric bioreduction of 1-boc-3-piperidine catalyzed by the TbADH and the coenzyme NADPH can be recycled by the BsGDH and cosubstrate glucose *in situ* (Scheme 1). The enzyme production and reaction efficiency were further improved *via* the optimization of microorganism cultivation and reaction condition, respectively.

## 2. Experimental

### 2.1 Chemicals

Starch and yeast power were purchased from Aladdin Industrial Corporation (Shanghai, China). Tryptone was supplied by China National Medicines Co. Ltd. (Beijing, China). Unless otherwise stated, all other chemicals were obtained from commercial sources and were of analytical grade.

### 2.2 Strains and culture conditions

The LB medium was used as seed medium, and the composition was (g L<sup>-1</sup>): yeast power 5; tryptone 10; NaCl 10; pH 7.0. The fermentation medium was optimized based on LB medium.

Recombinant *E. coli* BL21 (DE3) cells was inoculated into LB medium containing 50 mg L<sup>-1</sup> kanamycin and cultivated at

37 °C for 12 h on a rotary shaker (200 rpm). Then the seed culture was inoculated into 50 mL fermentation medium containing 50 mg L<sup>-1</sup> kanamycin and grown at 37 °C. After 3 h, IPTG was added to the culture with final concentration of 0.025 mM, and then the recombinant *E. coli* were continue cultivated at 40 °C for another 10 h for protein expression.

### 2.3 Construction of co-expression system of TbADH and BsGDH

The TbADH and BsGDH gene were synthesized by the Genaray Biotech (Shanghai) Co., Ltd. The exogenous gene was ligated into the first multi clone site (MCS) *via* *Bam*H/*Hind*III restriction sites, and the second MCS *via* the *Nde*I/*Xho*I restriction sites. The construction of recombinant pRSFDuet-1 plasmid and its transformation into *E. coli* were performed according to standard protocols.

### 2.4 Enzyme assay


To assay the activity of recombinant *E. coli* for reducing 1-boc-3-piperidinone, 10 mg of dry cell pellet was suspended in 950 μL phosphate buffer (pH 7.0, 200 mM) which contained 0.5% glucose. The mixture was incubated at 30 °C and 12 000 rpm on thermo-mixer compact (Zuofei Co., China) for 15 min. Then the substrate was added into the mixture with a final concentration of 50 mM and the reaction was carried out for 15 minutes under the same conditions. The sample was extracted twice with equal volume of ethyl acetate. The combined extracts were dried over anhydrous sodium sulfate and analyzed by gas chromatography (GC).

### 2.5 Optimization of culture conditions for recombinant *E. coli* BL21 (DE3)

The media composition and culture condition for recombinant *E. coli* were optimized through the 'one-factor-at-a-time'.<sup>20,21</sup> The factors of carbon source, nitrogen source, inducer, pH and temperature were varied in each experiment, and the corresponding cell mass and enzyme activity after cultivation were determined as described above.

### 2.6 Asymmetric reduction of *N*-boc-3-piperidone catalyzed by recombinant *E. coli* co-expressing alcohol dehydrogenase and glucose dehydrogenase

Whole cell of recombinant *E. coli* was used as biocatalyst in this study. The collected cells were resuspended into the phosphate buffer (pH 7.0, 200 mM) and were incubated at 30 °C for 15 min. Then, adequate amount of substrate, glucose, and NADP<sup>+</sup> were added into the suspension. The reaction mixture was incubated at 30 °C and 12 000 rpm on thermo-mixer compact (Zuofei Co., China). The reaction conditions including the initial pH, temperature, co-solvent, the amount of glucose and NADP<sup>+</sup> were optimized in this research. When the substrate concentration was increased to 500 mM, Na<sub>2</sub>CO<sub>3</sub> solution (1 M) or ammonia solution (5 M) was added to neutralize the gluconic acid formed during the reaction.



**Scheme 1** Asymmetric reduction of 1-boc-3-piperidinone to (*S*)-*N*-boc-3-hydroxy piperidine by recombinant *E. coli* with both TbADH and BsGDH activity.



## 2.7 Analytical methods

The conversion of the sample was analyzed by GC (GC-2010, Shimadzu Co., Japan) equipped with a  $\beta$ -DEX™ 120 Capillary Column (30 m  $\times$  0.25 mm  $\times$  0.25  $\mu$ m, Supelco, Sigma-Aldrich Co., USA). The carrier gas is nitrogen, and total flow is 20.0 mL min<sup>-1</sup>. The temperature of detector is set as 280 °C and injector's temperature is 230 °C. The oven program of the column temperature is as follows: 1 min at 100 °C, first ramp at 5 °C min<sup>-1</sup> to 150 °C (hold for 2 min), and second ramp at 2 °C min<sup>-1</sup> to 160 °C (hold for 2 min). The whole analysis process is 35 minutes. The retention time for 1-boc-3-piperidinone and NBHP were 28.9 min and 30.9 min, respectively.

The ee value of the product was analyzed by HPLC (LC 20AT, Shimadzu Co., Japan) using a chiral OD-H column (4.6 mm  $\times$  250 mm, Daicel Co., Japan). The mobile phase was hexane/isopropanol (97 : 3, by vol.). The extracted and dried samples were analyzed at 27 °C with the flow rate of 0.8 mL min<sup>-1</sup>, and the detection wavelength is 210 nm. The retention time for *S* and *R*-NBHP were 12.8 min and 13.9 min, respectively.

## 2.8 Preparative synthesis of *S*-NBHP

The preparative reduction of 1-boc-3-piperidinone was conducted at the substrate concentration of 0.5 M in a 20 ml aqueous buffer system containing 1 g recombinant *E. coli*. Glucose of 2.7 g was added for the NADPH regeneration. The reaction was carried out at 50 °C and ammonia solution (5 M) was periodical added to the reaction system for neutralizing the gluconic acid formed during the reaction. After the substrate was completely converted into product, the reaction mixture was extracted twice with equal volumes of ethyl acetate. Then the organic phase was combined, dried over anhydrous sodium sulphate and then evaporated in vacuum. The obtained yellow liquid was validated based on the chiral HPLC and <sup>1</sup>H NMR spectra.

## 3. Results and discussion

### 3.1 Construction of the recombinant plasmids co-expressing alcohol dehydrogenase and glucose dehydrogenase

Two kinds of recombinant pRSFduet-1 with different position of TbADH and BsGDH gene, pRSFduet-1-*tbadh*-*bsgdh* and pRSFduet-1-*bsgdh*-*tbadh* were constructed (Fig. S1†) and transformed into *E. coli* BL21(DE3). The expression of target protein was induced by addition of 0.1 mM IPTG. The enzyme activity for asymmetric reduction of 1-boc-3-piperidinone was determined as described in 2.4 to compare the efficiencies of these two kinds recombinant *E. coli* and the results were shown in the Table S1†. Both of the specific activity and activity of recombinant *E. coli* harboring pRSFduet-1-*tbadh*-*bsgdh* was inferior to the recombinant *E. coli* harboring pRSFduet-1-*bsgdh*-*tbadh*. The enzymes expression of the recombinant *E. coli* harboring pRSFduet-1-*bsgdh*-*tbadh* was further verified by SDS-PAGE (as shown in Fig. S2†), and the results showed that both TbADH and BsGDH expressed as soluble proteins. Therefore, the

recombinant *E. coli* harboring pRSFduet-1-*bsgdh*-*tbadh* was used in the subsequent study.

### 3.2 Optimization of culture conditions

**3.2.1 Effect of carbon source on cell growth and enzyme production.** Different carbon sources were selected to substitute the yeast in LB medium. Cell biomass and enzyme activity after cultivation on various medium were determined to evaluate the effect of carbon sources. As shown in Fig. 1A, when the starch was used as carbon source, enzyme activity was superior to that of other carbon source. In addition, the price of starch is cheap.

The concentration of starch was optimized in further work and the results revealed that the most appropriate concentration is 30 g L<sup>-1</sup>, and the activity is 98.4 U L<sup>-1</sup> (Fig. 1B). With the increase of starch concentration, the cell mass is increasing, however a decrease of activity was observed when the starch concentration exceed 30 g L<sup>-1</sup>. This may be due to the fact that something from sugar metabolism affects the enzyme production at high sugar concentration.

**3.2.2 Effect of nitrogen source on cell growth and enzyme production.** Nitrogen source is another important factor affecting cell growth and enzyme production. The commonly used nitrogen sources including inorganic and organic nitrogen were tested and the results are shown in Fig. 2A. Generally, the organic nitrogen is better than inorganic nitrogen. Among the




Fig. 1 Effect of carbon source (A) and its concentration (B) on cell mass (■) and enzyme activity (□). (A). Different carbon source were added into the medium. The recombinant *E. coli* was cultivated at the medium with different carbon source. After inoculation at 37 °C for 2 h, IPTG (0.1 mM) was added, and then cultivated at 30 °C for 12 h. (B). The recombinant *E. coli* was cultivated at the medium with different starch concentration. After inoculation at 37 °C for 2 h, IPTG (0.1 mM) was added, and then cultivated at 30 °C for 12 h.






Fig. 2 Effect of nitrogen source (A) and its concentration (B) on cell mass (■) and enzyme activity (□). (A). The recombinant *E. coli* was cultivated at the medium with different nitrogen source. After inoculation at 37 °C for 2 h, IPTG (0.1 mM) was added, and then cultivated at 30 °C for 12 h. (B). The recombinant *E. coli* was cultivated at the medium with different nitrogen concentration. After inoculation at 37 °C for 2 h, IPTG (0.1 mM) was added, and then cultivated at 30 °C for 12 h.

organic nitrogen, yeast power is the best choice. It not only promotes cell growth, but also increases enzyme activity.

The concentration of yeast power was further investigated and the results showed that the appropriate concentration is 15 g L<sup>-1</sup> with the highest enzyme activity of 105.4 U L<sup>-1</sup>. Although the amount of cells increased with the increasing of nitrogen source concentration, the metabolites of amino acids could inhibit the expression of the target protein when the concentration >15 g L<sup>-1</sup>.

**3.2.3 Effect of induction conditions on cell growth and enzyme production.** Both of the recombinant alcohol dehydrogenase and glucose dehydrogenase are under the control of T7 promoter, which can be induced by IPTG. The incubation time before IPTG added is of significant to the growth and enzyme production of recombinant *E. coli* BL21.<sup>22</sup> The recombinant *E. coli* BL21 was cultivated at 37 °C, and IPTG of 1 mM was added after incubation for 0–5 h. After incubation at 30 °C for another 10 h, the enzyme activity and cell mass were determined and the results were shown in Fig. 3A. The highest enzyme activity was obtained when IPTG was added after inoculation at 37 °C for 3 h.

IPTG with exorbitant concentrations might affect the growth of *E. coli* BL21 (DE3),<sup>23</sup> and the price of IPTG is expansive. Thus, IPTG with concentrations ranging from 0 to 1 mM were investigated and the results were shown in Fig. 3B. Between 0.1 to 1 mM, enzyme activity was similar. When IPTG concentration decreased to 0.025 mM, enzyme activity grows to 90.7 U L<sup>-1</sup>.




Fig. 3 Effect of induction time (A) and induction concentration (B) on cell mass (■) and enzyme activity (□). (A). Medium cultivated at 37 °C, 200 rpm for 0–5 h, then IPTG (0.1 mM) was added, cultivated at 30 °C, 200 rpm for 10 h. (B). Medium cultivated at 37 °C, 200 rpm for 3 h, then different concentrations of induction was added, cultivated at 30 °C, 200 rpm for 10 h.

Thus, the IPTG of 0.025 mM was added after inoculation for 3 h in the subsequent work.

### 3.2.4 Effect of pH on cell growth and enzyme production.

The effect of initial pH on cell growth and enzyme production of recombinant *E. coli* was examined with different initial pH ranging from 4.0 to 9.0 (Fig. 4A). The pH of the medium was adjusted to the desired value at the beginning using phosphoric acid or NaOH solution. Both the cells mass (5.3 g<sub>dew</sub> L<sup>-1</sup>) and specific activity (18.1 U g<sup>-1</sup>) reached the peak when the initial pH was adjusted to 6.0. As a result, an initial pH of 6.0 was used for further study.

**3.2.5 Effect of induced temperature on cell growth and enzyme production.** Temperature plays a non-negligible role during the protein expression. On the one hand, the cell growth is slow at low temperature. On the other hand, protein may be expressed as inclusion body at high temperature.<sup>24</sup> For exploring the optimal induce temperature, recombinant *E. coli* was cultivated at different temperature (20, 25, 30, 35, 40, 45 and 50 °C) after the addition of IPTG. As shown in Fig. 4B, enzyme activity is more sensitive to the temperature compared to cell mass. Both cell mass and enzyme activity reached the peak at 40 °C.

**3.2.6 Enzymatic synthesis of (S)-N-boc-3-hydroxy piperidine by whole cells cultivated in optimized media and LB media.** After optimization, the enzyme activity and cell mass reached 139.8 U L<sup>-1</sup> and 6.6 g<sub>dew</sub> L<sup>-1</sup>, which were approximately 11 times and 3.6 times of the original activity and cell mass, respectively. The performance of converting the substrate 1-boc-3-piperidinone into S-NBHP by the whole cell cultured in the initial medium or optimized medium were compared and the






Fig. 4 Effect of pH (A) and temperature (B) on cell mass (■) and enzyme activity (□). (A). Medium adjusted its initial pH (4.0 ~ 9.0) cultivated at 37 °C, 200 rpm for 3 h, then 0.025 mM IPTG was added, cultivated at 30 °C, 200 rpm for 10 h. (B). Medium cultivated at 37 °C, 200 rpm for 3 h, then 0.025 mM IPTG was added, cultivated in various temperature (20–50 °C), 200 rpm for 10 h, and the enzyme activity was measured in 200 mM sodium phosphate buffer (pH 6.0).

results were shown in Fig. 5. Using the cells cultivated in optimized medium as catalysts, the substrate 1-boc-3-piperidinone of 50 mM was almost entirely converted after 8 h, and the conversion reached 95%. However, the conversion of reaction catalyzed by cells cultivated in LB medium is only 56% after 8 h.

### 3.3 Optimization of enzymatic asymmetric reduction of 1-boc-3-piperidinone

**3.3.1 Effect of initial pH on the conversion of 1-boc-3-piperidinone.** The *N*-boc-3-piperidinone was reduced at various pH, ranging from 6 to 10, and the conversion after 10 h was measured to investigate the effects of pH on asymmetric




Fig. 5 Enzymatic reduction of 1-boc-3-piperidinone by whole cells cultured in the initial medium (●) or optimized medium (○). A reaction mixture consisting dry cell of 30 g L<sup>-1</sup> and 50 mM substrate in 0.2 M phosphate buffer (pH 7.0) was incubated at 30 °C and 200 rpm. Sample was taken at different time and the conversion was determined by GC.

Table 1 Effect of initial pH on the conversion of *N*-boc-3-piperidinone<sup>a</sup>

Buffer	pH	Conversion (%)
PBS	6	52.5 ± 2.8
	7	76.3 ± 1.8
	8	86.2 ± 0.1
Tris-HCl	8	73.4 ± 0.1
	9	74.6 ± 0.1
Gly-NaOH	9	70.4 ± 0.2
	10	56.4 ± 0.2

<sup>a</sup> The collected cells were resuspended into the following buffers (final concentration, 200 mM): sodium phosphate (pH 6–8) and Tris-HCl (pH 8–9) and Gly-NaOH (pH 9–10). The suspension was incubated at 30 °C, 1000 rpm in thermo shaker for 15 min, and then added the substrate and glucose with a final concentration of 50 mM. The reaction was carried out at 30 °C for 10 h.

reduction. As shown in Table 1, the highest conversion was obtained at the pH 8.0 in the PBS buffer. At acid or alkali solution, the whole cell biocatalysts exhibited lower catalytic efficiency.

**3.3.2 Effects of organic solvent types and the amount of their addition on the conversion of 1-boc-3-piperidinone.** The substrate 1-boc-3-piperidinone is not uniformly distributed in the aqueous phase. The addition of co-solvent into the reaction system is an efficient method to increase the solubility of the substrate. However, organic solvents always destroy the cell membrane or affect the enzyme activity. In the following work, different organic solvents with various concentrations were added into the reaction system and the conversion was measured to choose optimal co-solvent. Compared to the conversion (51%) in the reaction without co-solvent, a relative low conversion (<10%) was observed when the dimethyl sulfoxide used as co-solvent (Table 2), indicating the poor incompatibility of dimethyl sulfoxide. Similar conversions were obtained when the methanol and acetonitrile at the concentration of 5% (v/v) were used as co-solvent, 80.1% and 83.1%, respectively. However, the methanol is obviously superior to acetonitrile when the concentration >10% (v/v), indicating the great tolerance of this enzyme towards methanol. Thus, the methanol was chosen as the co-solvent in the subsequent work.

**3.3.3 Effects of glucose on the conversion of 1-boc-3-piperidinone.** Glucose acts as co-substrate to regenerate the

Table 2 Effects of organic solvents towards the conversion of *N*-boc-3-piperidinone<sup>a</sup>

	5%	10%	15%	20%
Methanol	80.1 ± 0.1	75.2 ± 0.2	68.7 ± 1.9	67.0 ± 2.4
Isopropyl alcohol	47.8 ± 2.5	21.4 ± 0.8	10.9 ± 0.3	6.3 ± 1.0
Acetonitrile	83.1 ± 0.5	46.4 ± 1.1	45.5 ± 0.8	2.5 ± 1.4
Dimethyl sulfoxide	9.7 ± 0.5	8.1 ± 0.4	7.4 ± 0.4	7.4 ± 0.4

<sup>a</sup> The collected cells were resuspended into PBS buffer (pH 8.0, 200 mM). The suspension was incubated at 30 °C, 1000 rpm in thermo shaker for 15 min, and then added the substrate and glucose with a final concentration of 50 mM. Various organic solvent were added into the reaction mixture with different final concentration (5%, 10%, 15% and 20%). The reaction was carried out at 30 °C for 10 h.



**Table 3** Effects of glucose concentration on the conversion of *N*-*boc*-3-piperidone<sup>a</sup>

Glucose (mM)	Glucose/substrate ( <i>n</i> : <i>n</i> )	Conversion (%)
25	0.5	55.7 ± 4.3
50	1.0	86.4 ± 0.4
75	1.5	91.1 ± 2.3
100	2.0	93.1 ± 0.9
125	2.5	94.4 ± 1.8


<sup>a</sup> Reaction condition: the collected cells were resuspended into PBS buffer (pH 8.0, 200 mM). The suspension was incubated at 30 °C, 1000 rpm in thermo shaker for 15 min, and then added the substrate (final concentration 50 mM) and glucose (final concentration of 25, 50, 75, 100 and 125 mM). Methanol of 5% (v/v) was used as the co-solvent. The reaction was carried out at 30 °C for 10 h.

NADPH by offering a molecule of [H] to NADP<sup>+</sup> catalysed by the GDH. However, the formed gluconic acid would result in the decrease of pH in reaction system. Various amounts of glucose were added into the reaction system, and the results showed that the conversion was increased obviously with the increase of the glucose amount. When the equivalent ratio was 1.5, the conversion reached 91%. However, the increase of conversion was not significant with further increase of glucose amount beyond 1.5 times to substrate. The amount of the co-substrate is determined to be 1.5 equivalents to substrate in the subsequent study (Table 3).

**3.3.4 Effects of temperature on the conversion of 1-*boc*-3-piperidone.** Enzymatic reactions usually have an optimum temperature. On the one hand, the reaction speed is faster at higher temperature. On the other hand, the temperature which is too high will lead to protein inactivation.

The bioreduction catalyzed by the recombinant *E. coli* was conducted at temperatures from 30 to 70 °C to investigate the effect of temperature. As shown in the Fig. 6, the conversion reached 96% after 10 h when the temperature was 30 °C. As the temperature increase, the reaction velocity increased gradually. At 50 °C, the conversion reached to 97.8% after 2 h, but as the temperature continues to rising, the reaction speed is reduced, which may be due to the enzyme inactivation. At 70 °C, the substrate was not converted (data no shown), and the enzyme may have been completely inactivated. The reaction was determined to be conducted at 50 °C in the subsequent work.

**3.3.5 Asymmetric reduction of 1-*boc*-3-piperidone by the recombinant *E. coli* with different catalyst loading.** The asymmetric reduction of *N*-*boc*-3-piperidone with different cell load was conducted without the addition of coenzyme, and the substrate concentration was increased to 500 mM. As shown in Fig. 7, the conversion reached 29.8%, 95.5%, 98.4% at 24 h when the cell load was 10, 30, 50 g L<sup>-1</sup>, respectively. A faster bioreduction was achieved when the cell load was increased, which is attributed to the increase of both catalysts and internal cofactors NADP<sup>+</sup> from the recombinant *E. coli*. Actually, the conversion reached 96.2% within merely 3 h when the cell load was increased to 50 g L<sup>-1</sup>, representing a relatively highspace-time yield (STY, 774 g L<sup>-1</sup> d<sup>-1</sup>) for *S*-NBHP. The highest STY




**Fig. 6** Effect of temperature on the conversion of *N*-*boc*-3-piperidone. The collected cells were resuspended into PBS buffer (pH 8.0, 200 mM). The suspension was incubated at 30 °C, 1000 rpm in thermo shaker for 15 min, and then added the substrate (final concentration of 50 mM) and glucose (final concentration of 75 mM). Methanol of 5% (v/v) was used as the co-solvent. The reaction was carried out at various temperatures (● 30; △ 40; ■ 50 and ◇ 60 °C) for 10 h. Sample was taken at different time and the conversion was determined by GC.

reported for *S*-NBHP was 552 g L<sup>-1</sup> d<sup>-1</sup> using the commercial ketone reductase as catalyst and extra glucose dehydrogenase was added to regenerate the coenzyme in this process.<sup>25</sup>

### 3.4 Asymmetric reduction of 1-*boc*-3-piperidone in preparative scale

Finally, the asymmetric reduction of *N*-*boc*-3-piperidone was conducted at preparative-scale (see Section 2.8 for details). Optically pure *S*-NBHP of 1.67 g was recovered in a total yield of 83% and >99% ee (Fig. S3†). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 3.78–3.81 (m, 1H), 3.71 (s, 1H), 3.58 (s, 1H), 3.01–3.06 (m, 1H), 2.99 (dd, *J* = 12.7, 8.0 Hz, 1H), 2.74 (s, 1H), 1.90 (s, 1H), 1.75–1.77 (m, 1H), 1.45 (s, 11H).



**Fig. 7** Asymmetric reduction of 1-*boc*-3-piperidone by *E. coli* BL21 harboring pRSFDuet-*bsgdh-tbadh* with different cell concentration. The collected cells were resuspended into PBS buffer (pH 8.0, 200 mM) with various concentration (■ 10; ● 30; and △ 50 g L<sup>-1</sup>). The suspension was incubated at 30 °C, 200 rpm in a shaker for 15 min, and then added the substrate (final concentration 500 mM) and glucose (final concentration of 750 mM). Methanol of 5% (v/v) was used as the co-solvent. The reaction was carried out at 50 °C for 24 h. Ammonia solution (5 M) was periodical added to the reaction system for neutralizing the produced acid during the reaction. Samples were taken at different time and the conversion was determined by GC.



## 4. Conclusions

A recombinant *E. coli* BL21 (DE3) was constructed for co-expressing alcohol dehydrogenase and glucose dehydrogenase using the plasmid pRSFduet-1, which contains two multiple clone sites. The application potential of the constructed recombinant *E. coli* harbouring pRSFduet-1-*bsgdh-tbadh* was further improved through the optimization of the enzyme production condition and reaction condition. Finally, the bio-reduction catalyzed by the recombinant *E. coli* was conducted at the substrate concentration of 500 mM without external addition of cofactors, giving satisfactory conversion (96.2%) and enantiomeric excesses for *S*-NBHP (ee value > 99%). The STY reported in this study ( $774 \text{ g L}^{-1} \text{ d}^{-1}$ ) was the highest reported for *S*-NBHP preparation so far. *S*-NBHP was obtained in a preparative experiment in 83% isolated yield and 99% ee value. Thus, the recombinant *E. coli* harbouring pRSFduet-1-*bsgdh-tbadh* was competitive and promising compared to other biocatalysts for asymmetrically reducing 1-boc-3-piperidinone. Further work about the immobilization of this recombinant *E. coli* and optimization of the reaction for large scale preparation is in the progress.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was financially supported by Shanghai Collaborative Innovation Center of Fragrance, Flavor and Cosmetics (1021ZK170004002), the Shanghai Institute of Technology (YJ2015-36) and Shanghai Municipal Education Commission (ZZyxy15011).

## References

- 1 Y. Chen, Y. Xu and J. B. Chen, *MATEC Web Conf.*, 2015, **22**, 1–5.
- 2 I. Dragutan, V. Dragutan and A. Demonceau, *RSC Adv.*, 2012, **2**, 719–736.
- 3 T. J. Harrison, B. O. Patrick and G. R. Dake, *Org. Lett.*, 2007, **9**, 367–370.
- 4 W. Y. Shen, Z. C. Shen, Z. Hu, Y. L. Lin and J. M. Wang, *Chin. J. Pharm.*, 2013, **44**, 436–437.
- 5 M. S. Reddy, M. Narender and K. R. Rao, *Tetrahedron*, 2007, **63**, 331–336.

- 6 G. W. Zheng, H. L. Yu, J. D. Zhang and J. H. Xu, *Adv. Synth. Catal.*, 2009, **351**, 405–414.
- 7 Y. Ni, J. Y. Zhou and Z. H. Sun, *Process Biochem.*, 2012, **47**, 1042–1048.
- 8 X. T. Zhou, R. Z. Zhang, Y. Xu, H. B. Liang, J. W. Jiang and R. Xiao, *Process Biochem.*, 2015, **50**, 1807–1813.
- 9 Q. Y. Wang, T. T. Ye, Z. Z. Ma, R. Chen, T. Xie and X. P. Yin, *J. Ind. Microbiol. Biotechnol.*, 2014, **41**, 1609–1616.
- 10 R. Lacheretz, D. G. Pardo and J. Cossy, *Org. Lett.*, 2009, **11**, 1245–1248.
- 11 Z. T. Sun, R. Lonsdale, A. Ilie, G. Li, J. Zhou and M. T. Reetz, *ACS Catal.*, 2016, **6**, 1598–1605.
- 12 X. Ju, Y. Y. Tang, X. L. Liang, M. Q. Hou, Z. H. Wan and J. H. Tao, *Org. Process Res. Dev.*, 2014, **18**, 827–830.
- 13 H. M. Zhao and V. D. D. WA, *Curr. Opin. Biotechnol.*, 2003, **14**, 583–589.
- 14 F. Hollmann and A. Schmid, *Biocatal. Biotransform.*, 2004, **22**, 63–88.
- 15 G. W. Huisman, J. Liang and A. Krebber, *Curr. Opin. Chem. Biol.*, 2010, **14**, 122–129.
- 16 M. Kataoka, L. P. S. Rohani, M. Wada, K. Kita, H. Yanase, I. Urabe and S. Shimizu, *Biosci., Biotechnol., Biochem.*, 1998, **62**, 167–169.
- 17 H. Gröger, F. Chamouveau, N. Orologas, C. Rollmann, K. Drauz, W. Hummel, A. Weckbecker and O. May, *Angew. Chem., Int. Ed.*, 2006, **45**, 5677–5681.
- 18 M. Peretz, O. Bogin, S. Tel-Or, A. Cohen, G. Li, J. S. Chen and Y. Burstein, *Anaerobe*, 1997, **3**, 259–270.
- 19 K. Yamane, M. Kumano and K. Kurita, *Microbiology*, 1996, **142**, 3047–3056.
- 20 A. Banerjee, P. Kaul and U. C. Banerjee, *Appl. Microbiol. Biotechnol.*, 2006, **72**, 77–87.
- 21 A. K. Khandelwal, V. K. Nigam, M. K. Mohan, P. Ghosh and B. Choudhury, *J. Chem. Technol. Biotechnol.*, 2007, **82**, 645–651.
- 22 J. F. Liu, Z. J. Zhang, A. T. Li, J. Pan and J. H. Xu, *Appl. Microbiol. Biotechnol.*, 2011, **89**, 665–672.
- 23 P. Dvorak, L. Chrast, P. I. Nikel, R. Fedr, K. Soucek, M. Sedlackova, R. Chaloupkova, V. Lorenzo, Z. Prokop and J. D. Dvorak, *Microb. Cell Fact.*, 2015, **14**, 201–215.
- 24 X. Wu, X. D. Gou and X. J. Chen, *Process Biochem.*, 2015, **50**, 104–110.
- 25 W. Zhu, B. Wang, Q. P. Zhang, H. Wu and B. H. Li, CN Patent 104059952 A, Syncozymes (Shanghai) Co., Ltd., 2014.

